Mike, and afternoon, everyone. you, Thank good
As our to will quarter before a always quarter, thank three continued strategies. financials. for advance overview discuss Neovasc, our and update give of as today. value creation was Chris I to QX a business over to we call you the joining the for strong us an turning operationally
trial We with our revenues. to We advance in Reducer US-based results Europe. are advancing to sales efforts particularly our for made to generating pleased to COSIRA-II reduced great progress preparations begin reimbursement continue and secure in record Reducer for
of we into executed Chris first some to cash expected and initiatives we footing and XXXX our mid extend are the have half further will solidified Importantly, financial of runway which our XXXX, are in discuss. the
have elsewhere our additional new Austrian. Kingdom, Europe of of just refractory change during for Italy, and seen lingering recorded no has can efforts working The United top the to over see these driving revenues to the in the including of as line is pillars Neovasc hard market gratifying markets throughout expanding in marketing despite and and of salespeople coverage. people the reimbursement benefits quarter traditional direct the Europe, the strategy record and as COVID in is the three the value-creation angina Europe, Reducer partnerships of Reducer of of into Switzerland how lives Spain, other distributor growing with Reducer options. expanding acceptance outside and first-hand Netherlands treatment we efforts, of use One the issues the and Reducer in $XXX,XXX States Europe. seen be through we use It United can of
the pursue foundation and this the for value We believe systems brings convinced in the the United the countries. are Germany. our We specific are think to us Reducer success these Reducer we to using on have tangible outcomes. we based we the help in healthcare objectives coming and will for believe the and make are progress continue further news benefits multiple continue We to France reimbursement stories in clear we States, more to patients alike reimbursement is Kingdom, with to that in months United
Turning United promote in approval and to gain efforts for the Reducer our to States.
towards Our XXXX to X aim Coursera And important needed advance in look to ability PMA the the clinical in appropriate trial statistically size significant key sites, achieving approvals as of patients up and the for clinical labs in we an The qualifying in our of to the nd organization called enrollment FDA. we patients for patient of to initiative to With the the to are trial the core board for and and of IDE US the reviewing Canadian in We meantime, interim important enrollment of will when suited clinical track of sites. on and investigate Reducer the here future with In our with United we XXXX. first on likelihood XX% selection submission adjust enrol institutional an obtaining a up contracts study the trial remain and efficacy example, and tolerance study secured, service trial. September from months first exercised supporting approval milestone are endpoint The to the US six the States protocol XXXX, for increase QX designed results. is sample the received the the expect after XX review the the achieved sites working approximately with on to approval refractory this initiating enrol in in is suffering clinical research providers, several new we an FDA. best safety patients the of the be from we angina. primary protocol XXX
for in successfully gov the of registration [ph] trials the have filed In addition, system. X Coursera clinical dot we
a Finally, working This during on payment is that we finding the complex US clinical and path undertaking all certain initiated coverage device towards Coursera a the have and trial. CMS, outcome by reimbursement our are at request. for we not X is
to see also flow continue data. We a of positive steady
quarter, of and significant featured improvement Early out in was recently in society, life published Polish study the results years. in Reducer October, the have improvement real-world evaluated as example, trials side a and end in as The journal ischemia. with study the profile been published the Heart near REDUCER-X with an a score were angina in confirmed right patients data article the the two sustained study measure demonstrated the from For well More the strong Intervention. cardiovascular patients to chest ischemia. Canadian the Euro The primarily safety a of of article quality the in conducted of pain angina Reducer severity Journal. in in in side severity statistically left this
demonstrated heart consecutive and implantation experts the that physicians, advanced the upon Reducer. demonstrated could We leading and were diagnostic humans in very continue improvement physicians the absolute the flow the pleased in Reducer blood about coronary two efficacy world-renowned the Recently, positive of the into supports of safety the muscle a flow results. very in both be tools two European in to of physiology using is first meaningful The data science. This patients. very most time emphatic be coronary this with
an potential the to the relieve action demonstrate vessels Reducer. blood. is were able the to flow Increasing because to blood time, the points here, experienced coronary first the angina increase occluded it heart. muscle. may muscle immediate chest the era a More associated blood is muscle of to of key of the implantation in heart Patients resulted physicians but angina. is in still the of option with in for Reducer the of signify to to optimal work beginning For This enough flow time blood treatment and a doesn't cardiology the the is oxygenated that get of mechanism when done heart pain in real potentially the new important be the development interventional to this critical sinus
our to our advance technology. Tiara to on efforts Moving
As in its advanced paused to work device we on transfemoral the is program. aware, the stage which are focus of Tiara than more on device, development transfemoral you the many Tiara transapical
We resultant we new European continue decision in CE to rules late first the of and would MDR targeting work half our to application year with the transapical balance actions sheet. took our effect a during the or are and XXXX. notified some body Device on our also Tiara advance revisit in Europe of regulation the the under Medical the for we Mark I
rules. IDE allows which for we and did headcount XXXX, corporate the at of the is which Coursera to current a regain the reduction. fact some runway Neovasc significant reduction made made we comment Reducer. we And the would clinical recall, compliance the before will I to on to into development we suspension in significant over are of the NASDAQ like you of our with a focus Overall, opportunity to, extending Chris, us our mid burn execute half included to with least pleased turn now in that call to Last we and decisions listing position I trial this progress a have going of on of system, among forward. year. the transfemoral quarter our believe cash decisions first the These take result many As new other cash on in difficult during centered X strategy, things Tiara
We currently and been you the minimum period closing of before XXXX. NASDAQ breach can November breach. price time. are an can achieve though short above grace this XX, likely days $X may initial still granted the cure cure that As this this are unlikely to by remaining rule, $X have be bid period consecutive aware, in we It XX we of trading breach we in
eligible second believe us we and be However, this do XX, XXX-day to a NASDAQ for giving until we May according XXXX, rules guidelines, period cure breach. time grace could to that additional the
for is $X.X last which make remains in the NASDAQ in satisfying to XXX-day period will only or requirement, weeks, meet XXXX. all period to second cure a being shareholder's granted grace XX, believe the would and remaining to this grace rules. requirements. grace a on are than $XX November million additional of the grace second us that will shareholder's on $XX million Neovasc. coming the decide day out after equity applicable our application to able is while glad point the February in for eligibility period placed market equity greater we but that NASDAQ be like an the the We a also period to initial has for year in not see I position of stronger this potential to requirement pathway there we the And financing Overall, the listing that capitalization NASDAQ breach million a also
We We year. we're beginning see strong also our wise, of of over believe operational a and goals the financial we great the first a have and advancing accomplished deal third next six but adoption plan Reducer quarter, made in months. during the expand benefits difficult the half some the reimbursement to to the we decisions of
there on to is and understand fronts, the balance positive all milestones more we for we However to and of done hope be XXXX during be more beyond.
continued our Chris our over Chris? investors, now our review want all customers our of to financial will employees for we Neovasc. always for of call I their a to the thank results. and turn As support
